Prospective study of definitive chemoradiotherapy with S-1 and nedaplatin in patients with stage II/III (non-T4) esophageal cancer

Esophagus ◽  
2011 ◽  
Vol 8 (1) ◽  
pp. 45-51 ◽  
Author(s):  
Takashi Tsuda ◽  
Hiroyuki Inaba ◽  
Aya Miyazaki ◽  
Naoki Izawa ◽  
Mami Hirakawa ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Prospective Study ◽  
Stage Ii ◽  
Definitive Chemoradiotherapy ◽  
T4 Esophageal Cancer

PS02.031: DEFINITIVE CHEMORADIOTHERAPY WITH DOCETAXEL, CISPLATIN, AND 5-FLUOROURACIL (DCF-R) FOR ADVANCED CERVICAL ESOPHAGEAL CANCER

2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 128-129
Author(s):  
Hiroshi Okamoto ◽  
Yusuke Taniyama ◽  
Tadashi Sakurai ◽  
Takahiro Heishi ◽  
Chiaki Sato ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Cancer ◽  
Lymph Node ◽  
Survival Rate ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Conflicts Of Interest ◽  
Clinical Stage ◽  
Stage Ii ◽  
Definitive Chemoradiotherapy

Abstract Background Recently, definitive chemoradiotherapy (dCRT) has become one of the essential treatment strategies for esophageal squamous cell carcinoma (ESCC) and has been especially gaining prevalence for cervical ESCC to preserve the larynx. There have been recent reports on favorable outcomes of docetaxel/CDDP/5-FU (DCF-R) for advanced esophageal cancer. Our department recently introduced DCF-R for treating advanced cervical ESCC. We analyzed the safety and outcomes of DCF-R in patients with advanced cervical ESCC. Methods We retrospectively evaluated 12 advanced cervical ESCC patients (clinical stage II–IV, including T4b and/or M1 lymph node) in our department who received DCF-R as the first-line treatment between December 2010 and February 2015. Results Our patient cohort comprised 9 males and 3 females (median age, 67.5 years; range: 54–76 years). All patients were squamous cell carcinoma. The median observation period was 34.5 (8–80) months with total irradiation dose of 64.0 (60–70) Gy. The pretreatment clinical stage (according to Union for International Cancer Center) included one stage II, seven stage III, and four stage IV cases (including 3 patients with T4b [2 trachea and 1 thyroid] and 4 patients with M1 lymph node. We attained complete response (CR) in 10 patients and stable disease in 2 patients. Of 10 patients with CR, 5 experienced recurrence and 5 continued exhibiting CR. Two persistent patients included one patient who died of cancer and one patient who underwent salvage surgery. Furthermore, grade 3 or more adverse events as defined in Common Terminology Criteria for Adverse Event version 4 included leucopenia (91.7%), neutropenia (91.7%), febrile neutropenia (50%), and pharyngeal pain (50%). There was no treatment-related mortality and treatment schedules were completed in all patients, although dose reduction of the second cycle of chemotherapy was required in four patients (33%) and change in the radiation schedule was required in one patient (8.3%). While the 2-/3-/5-year overall survival rate was 66.7%/48.6%/48.6%, the 2-/3-/5-year recurrent-free survival rate was 58.3%/50.0%/37.5%, respectively. Conclusion DCF-R treatment for advanced cervical ESCC could be completed by the careful administration, and although a strong blood toxicity might occur, a favorable prognosis can be obtained with larynx preservation. Disclosure All authors have declared no conflicts of interest.

Long-Term Outcome of Definitive Chemoradiotherapy and Induction Chemoradiotherapy Followed by Surgery for T4 Esophageal Cancer with Tracheobronchial Invasion

2018 ◽  
Vol 25 (11) ◽  
pp. 3280-3287 ◽  
Author(s):  
Shohei Yamaguchi ◽  
Masaru Morita ◽  
Manabu Yamamoto ◽  
Akinori Egashira ◽  
Hiroyuki Kawano ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Definitive Chemoradiotherapy ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Induction Chemoradiotherapy ◽  
T4 Esophageal Cancer

T4 esophageal cancer treated with radical resection

2020 ◽  
Vol 61 (4) ◽  
Author(s):  
Hai Zhong ◽  
Qianjun Li ◽  
Wenhui Gao ◽  
Xiang Li ◽  
Junhua Zhang ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Radical Resection ◽  
T4 Esophageal Cancer

scholarly journals Salvage esophagectomy for local recurrent esophageal cancer after definitive chemoradiotherapy followed by photodynamic therapy: A case report

2021 ◽  
Vol 80 ◽  
pp. 105617
Author(s):  
Wataru Hirose ◽  
Yusuke Taniyama ◽  
Fumiyoshi Fujishima ◽  
Chiaki Sato ◽  
Michiaki Unno ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Photodynamic Therapy ◽  
Case Report ◽  
Definitive Chemoradiotherapy ◽  
Salvage Esophagectomy

Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients

2004 ◽  
Vol 60 (5) ◽  
pp. 1484-1493 ◽  
Author(s):  
Zhongxing Liao ◽  
Zhen Zhang ◽  
Jing Jin ◽  
Jaffer A. Ajani ◽  
Stephen G. Swisher ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Cancer Patients ◽  
Concurrent Chemoradiotherapy ◽  
Clinical Stage ◽  
Stage Ii ◽  
Locoregional Control
Sign in / Sign up

Export Citation Format

Share Document